Navigation Links
EXAMINE-Studie zur kardiovaskulären Sicherheit von Alogliptin erreicht primären Endpunkt: keine Erhöhung des kardiovaskulären Risikos bei Risikopatienten mit Typ-2 Diabetes
Date:9/11/2013

AMSTERDAM, Niederlande, und OSAKA, Japan, 11. September 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) gab heute die Ergebnisse der Studie zur kardiovaskulären Sicherheit EXAMINE bekannt. EXAMINE steht für EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE (Vergleich des kardiovaskulären Outcomes – Alogliptin vs. Standardtherapie). Die Studie wurde bei Patienten mit Typ 2 Diabetes, die bereits ein akutes Koronarsyndrom hinter sich hatten, durchgeführt, die auf Basis einer Standardtherapie entweder Alogliptin oder Placebo erhielten. Es konnte gezeigt werden, dass das Risiko für ein kardiovaskuläres Ereignis in beiden Gruppen vergleichbar war. Damit konnte die Anforderung der „Non-Inferiority" („Nicht-Unterlegenheit") für Alogliptin erfüllt werden. Der primäre Endpunkt der Nichtinferiorität gegenüber Placebo auf Basis der Standardtherapie bei einer Patientenpopulation mit Diabetes Typ 2 und erhöhtem Risiko für ein kardiovaskuläres Ereignis wurde erreicht. Diese im New England Journal of Medicine (NEJM) veröffentlichten und auf dem ESC Congress 2013 vorgestellten Daten belegen, dass Alogliptin das kardiovaskuläre Risiko von Patienten mit Diabetes Typ 2, bei denen aufgrund eines kurz zuvor aufgetretenen akuten Koronarsyndroms (ACS) ein hohes Risiko für ein schwerwiegendes kardiovaskuläres Ereignis (major adverse cardiovascular event,  MACE) besteht, nicht erhöht. Der primäre Endpunkt bestand aus folgenden Komponenten: kardiovaskulär bedingter Tod, nicht tödlicher Herzinfarkt, nicht tödlicher Schlaganfall. Der primäre Endpunkt trat in der Alogliptin und in der Placebo-Gruppe mit ähnlicher Häufigkeit auf: bei 11,3 % der Patienten der Alogliptin-Gruppe bzw. bei 11,8 % der Patienten der Placebogruppe
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. American College of Chest Physicians (ACCP) und Simbionix arbeiten zusammen, um klinische Ausbildung und Patientensicherheit zu verbessern
2. Messe/Konferenz InnoPack Pharma legt den Fokus auf innovative Verpackungen für Compliance und Sicherheit
3. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
4. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
5. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
6. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
7. National Diabetes Volunteer Leadership Council (NDVLC) Urges FDA to Enforce Stringent Accuracy Standards for Blood Glucose Monitoring Systems
8. Clinilabs Sponsors The ADAs 2013 Step Out: Walk to Stop Diabetes
9. GSMA mHealth Grand Tour Highlights How Mobile Technology Could Help Prevent 5 Million People In The EU From Developing Diabetes
10. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
11. Bio-Solutions Corp. Expanding in Booming Diabetes Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)...  EndoChoice Holdings, Inc. (NYSE:  GI) announced today that ... on Thursday, August 6, 2015 before the market open. ... on Thursday, August 6, 2015 at 9:00 a.m. ET ... 807-9684 for domestic callers and (412) 317-5415 for international ... be available on the investor relations section of the ...
(Date:7/6/2015)... 2015  OrthoSpace Ltd. ("OrthoSpace" or "Company") announced ... in its US Investigational Device Exemption (IDE) pivotal ... single blinded control study that compares the Company,s ... partial repair for the treatment of full thickness ... commercially available outside of the United ...
(Date:7/6/2015)... - The Canadian Pharmacists Association (CPhA) urges the federal government ... all Canadians have the opportunity to protect themselves against ... The lack of access to HPV vaccination programs for ... needlessly putting the health of Canadians at risk. ... pose a significant threat to the health of Canadians," ...
Breaking Medicine Technology:EndoChoice to Report Second Quarter 2015 Financial Results on August 6, 2015 2OrthoSpace Enrolls First Patients in US IDE Study 2CPhA Calls for HPV Strategy for Young Men to Save Lives 2
... MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, manufacturer ... processed from human amniotic membrane, announced today its results ... 30, 2011. The Company recorded record revenue ... over second quarter of 2011 revenue of $1,929,000 and ...
... Oct. 26, 2011 Reportlinker.com ... research report is available in ... Early Stage Drug Safety Strategies ... towards achieving clinical success ...
Cached Medicine Technology:MiMedx Group Announces Third Quarter 2011 Results 2MiMedx Group Announces Third Quarter 2011 Results 3MiMedx Group Announces Third Quarter 2011 Results 4MiMedx Group Announces Third Quarter 2011 Results 5MiMedx Group Announces Third Quarter 2011 Results 6MiMedx Group Announces Third Quarter 2011 Results 7MiMedx Group Announces Third Quarter 2011 Results 8MiMedx Group Announces Third Quarter 2011 Results 9MiMedx Group Announces Third Quarter 2011 Results 10Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 2Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 3Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 4Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 5Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 6Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 7Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 8
(Date:7/7/2015)... ... , ... Dr. Poneh Ghasri , cosmetic dentist in Los Angeles, is ... one of the fastest, easiest ways to brighten a smile. Stained teeth can add ... confidence. With the right teeth whitening treatment, patients can restore a more youthful appearance ...
(Date:7/7/2015)... ... 2015 , ... Office Practicum announced today that it has ... effective July 6th, 2015. Ellen joins Office Practicum with more than 27 years ... chemical company to early and growth-stage technology companies. , Purdy joins Office ...
(Date:7/7/2015)... ... July 07, 2015 , ... ISI ... announced the release of Service Pack 5600 for its Call Accounting and ... enhancements to the already robust capabilities of the reporting platform, including updates ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... Connexion Point is holding an onsite job ... be held at 1769 Paragon Place, Suite 100, this upcoming Wednesday, July 8, and Thursday, ... fair, Connexion Point will be recruiting new applicants as well as holding onsite interviews. ...
(Date:7/6/2015)... Angeles, CA (PRWEB) , ... July 06, 2015 , ... ... for finding medical providers for personal injury victims. Throughout the company’s history the ... collectively deliver the care victims need in their recovery. And while Doctors on ...
Breaking Medicine News(10 mins):Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 3Health News:Office Practicum Announces new CFO 2Health News:ISI Telemanagement Solutions, Inc. Releases Service Pack 5600 for Infortel® Select 2Health News:Connexion Point, a tech enabled healthcare services company, is holding on-site job fair July 8th and 9th to fill 400 positions at its new Memphis location 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 3
... April 30 Retirement Living TV (RLTV) ... to bring a compelling,dialogue on the healthcare ... Virginia and Southern Delaware television markets through ... The nation,s leading,political and public leaders present ...
... April 30 Brown & Toland Medical Group,today announced ... of $12 million on total revenues of $235 million., ... million for,pay for performance and other related bonuses from ... distribute an additional $8.2,million in bonus payments to eligible ...
... study finds antidepressant cut inflammation in relapsing remitting ... may help reduce disease activity in people with the ... study suggests. , Forty patients with the disease were ... of fluoxetine (Prozac) or a placebo for 24 weeks. ...
... in heart rate variability, researchers report, , , WEDNESDAY, April ... show that the electromagnetic field produced by incubators affect ... , Whether these changes in cardiac rhythms have long-term ... premature infants who can spend several weeks or months ...
... during its Q1 2008 ... conference call on May 8 -, ... the "Company") (NASDAQ: SXCI , TSX: SXC), a leading provider,of ... (NASDAQ: NMHC ), announce that the previously,announced acquisition of NMHC ...
... to Both Reduce Exacerbations ... and Improve Lung Function, ... and Drug Administration today approved Advair Diskus(R) 250/50,(fluticasone propionate 250 ... exacerbations in patients with chronic obstructive,pulmonary disease (COPD) who have ...
Cached Medicine News:Health News:Retirement Living TV Partners with Maryland Public Television to Address the Issue of Healthcare in America Through Its Series Healthcare '08: Search for Solutions 2Health News:Retirement Living TV Partners with Maryland Public Television to Address the Issue of Healthcare in America Through Its Series Healthcare '08: Search for Solutions 3Health News:Brown & Toland Announces 2007 Financial Results 2Health News:Prozac Reduces Disease Activity in MS Patients 2Health News:Incubators Affect Newborns' Heart Rates 2Health News:SXC Health Solutions completes acquisition of NMHC 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 3Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 4
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance....
The Smart Check Syphilis Device is a qualitative membrane device based immunoassay for the detection of TP (Treponema Pallidum) antibodies in whole blood/serum/plasma. For professional in vitro diagn...
Bio-Quant, Inc. OneStep hCG InstaTest is an immunochromatographic assay designed for qualitative determination of human chorionic gonadotropin (hCG) in urine for early detection of pregnancy....
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu...
Medicine Products: